said Catherine Stehman-Breen.

From Sept. 16-20, 2011 .’The breadth of data getting presented as of this year’s Annual Conference demonstrates Amgen’s continued commitment to advancing the scientific understanding of bone biology,’ said Catherine Stehman-Breen, M.D., vice president of Global Development at Amgen. ‘Significantly, the eight yr data from our Stage 2 extension study works with the long-term efficacy and protection profile of Prolia for females with postmenopausal osteoporosis at improved threat of fractures.’ ASBMR abstracts can be found and can be looked at online at Identified are selected abstracts of interest about Amgen research below.

Pratt said. Dr. He said he expects that this and additional studies will convince doctors to try the amiloride or spironolactone alternatives rather. Dr. Pratt stated the study was conducted with African-American patients because they are on average even more predisposed to retain sodium, but he believes the potency of both drugs likely will be the same regardless of ethnicity.. Spironolactone and Amiloride can help patients with high blood pressure Two inexpensive but broadly overlooked drugs may help many patients who continue steadily to have high blood circulation pressure despite taking standard blood pressure medications, according to research simply by Indiana University School of Medicine scientists.